Why NervGen?

Significant Milestones
On Track For 2023

This website may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities legislation. Many factors could cause NervGen’s actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements including factors set forth in the NervGen’s filings on SEDAR which can be found on www.SEDAR.com. Readers should not place undue reliance on forward-looking statements made within this website. Furthermore, NervGen has no intention and undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Key Upcoming Value Drivers

  1. Phase 1 clinical trial completion

  2. Phase 1b/2a spinal cord injury clinical trial to be initiated

  3. Preclinical study results in an Alzheimer’s disease model

  4. Awarding of US Department of Defense and privately funded grants

NervGen Pharma Corp. (OTCQX: NGENF, TSX-V: NGEN) is developing a first-in-class neuroreparative drug for the treatment of nervous system damage

NervGen’s lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial.

The company’s initial target indications are spinal cord injury, Alzheimer’s disease and multiple sclerosis.

In the US alone:


People Living with Spinal Cord Injury1


People Living with Alzheimer’s2


People Living with Multiple Sclerosis3

1. National Spinal Cord Injury Statistical Center, 2021 Fact Sheet

2. Alzheimer’s Association

3. National Multiple Sclerosis Society

Dramatic Pre-Clinical Results

“If these results translate to patients, NVG-291 could redefine the treatment of spinal cord injury.”

Monica A. Perez, PT, PhD
Scientific Chair of the Arms + Hands Lab at Shirley Ryan AbilityLab; Professor of Physical Medicine & Rehabilitation at Northwestern University; and Research Scientist at the Edward Hines Jr. VA Hospital

“NervGen’s platform technology is truly unique and will be of significant interest in the search for a solution to Alzheimer’s disease.”

George Perry, PhD
Current and founding Editor-in-Chief of the Journal of Alzheimer’s Disease and Semmes Distinguished University Chair in Neurobiology at the University of Texas, San Antonio Hospital



Huitt Tracey

Corporate Communications
(604) 537-2094



Nancy Thompson

Vorticom, Inc.
(212) 532-2208


Leave a Reply

Your email address will not be published. Required fields are marked *